Stock Track | EVEREST MED Soars 9.80% Intraday on Strong Annual Results with 142% Revenue Growth and First-Time Profitability

Stock Track03-27

EVEREST MED's stock price soared 9.80% during intraday trading, reflecting strong investor optimism following the release of its annual financial results.

The surge is attributed to the company's impressive annual performance, which included a 142% year-on-year increase in full-year revenue to RMB 1.707 billion. Notably, EVEREST MED achieved profitability for the first time under non-IFRS measures, recording a profit of RMB 187 million, while its loss under International Financial Reporting Standards (IFRS) narrowed significantly by 71%. Operating cash flow also turned positive, with the revenue growth primarily driven by increased sales of its product Nefecon in commercialized markets.

The company stated that 2026 will be a critical "year of execution" for its strategic goals, with Nefecon expected to remain the core growth engine for sales revenue. EVEREST MED plans to advance the inclusion of its products in national reimbursement negotiations, accelerate global clinical development of its pipeline, seek partnership opportunities, and expand its therapeutic coverage, contributing to the positive market sentiment.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1119261107?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-27 10:13","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1119261107","market":"us","top_or_hot":-1,"title":"Stock Track | EVEREST MED Soars 9.80% Intraday on Strong Annual Results with 142% Revenue Growth and First-Time Profitability","media":"Stock Track","content":"<p>EVEREST MED's stock price soared 9.80% during intraday trading, reflecting strong investor optimism following the release of its annual financial results.</p><p>The surge is attributed to the company's impressive annual performance, which included a 142% year-on-year increase in full-year revenue to RMB 1.707 billion. Notably, EVEREST MED achieved profitability for the first time under non-IFRS measures, recording a profit of RMB 187 million, while its loss under International Financial Reporting Standards (IFRS) narrowed significantly by 71%. Operating cash flow also turned positive, with the revenue growth primarily driven by increased sales of its product Nefecon in commercialized markets.</p><p>The company stated that 2026 will be a critical \"year of execution\" for its strategic goals, with Nefecon expected to remain the core growth engine for sales revenue. EVEREST MED plans to advance the inclusion of its products in national reimbursement negotiations, accelerate global clinical development of its pipeline, seek partnership opportunities, and expand its therapeutic coverage, contributing to the positive market sentiment.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | EVEREST MED Soars 9.80% Intraday on Strong Annual Results with 142% Revenue Growth and First-Time Profitability</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | EVEREST MED Soars 9.80% Intraday on Strong Annual Results with 142% Revenue Growth and First-Time Profitability\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-03-27 10:13</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>EVEREST MED's stock price soared 9.80% during intraday trading, reflecting strong investor optimism following the release of its annual financial results.</p><p>The surge is attributed to the company's impressive annual performance, which included a 142% year-on-year increase in full-year revenue to RMB 1.707 billion. Notably, EVEREST MED achieved profitability for the first time under non-IFRS measures, recording a profit of RMB 187 million, while its loss under International Financial Reporting Standards (IFRS) narrowed significantly by 71%. Operating cash flow also turned positive, with the revenue growth primarily driven by increased sales of its product Nefecon in commercialized markets.</p><p>The company stated that 2026 will be a critical \"year of execution\" for its strategic goals, with Nefecon expected to remain the core growth engine for sales revenue. EVEREST MED plans to advance the inclusion of its products in national reimbursement negotiations, accelerate global clinical development of its pipeline, seek partnership opportunities, and expand its therapeutic coverage, contributing to the positive market sentiment.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01952","symbol_name":"云顶新耀","start_time":0,"source_url":"","article_id":"1119261107","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1119261107","pubTimestamp":1774577628,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"EVEREST MED's stock price soared 9.80% during intraday trading, reflecting strong investor optimism following the release of its annual financial results.The surge is attributed to the company's...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01952":"云顶新耀"},"translate_title":"个股赛道|EVEREST MED盘中飙升9.80%营收增长142%首次盈利强劲年度业绩","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01952":1},"content_text":"EVEREST MED's stock price soared 9.80% during intraday trading, reflecting strong investor optimism following the release of its annual financial results.The surge is attributed to the company's impressive annual performance, which included a 142% year-on-year increase in full-year revenue to RMB 1.707 billion. Notably, EVEREST MED achieved profitability for the first time under non-IFRS measures, recording a profit of RMB 187 million, while its loss under International Financial Reporting Standards (IFRS) narrowed significantly by 71%. Operating cash flow also turned positive, with the revenue growth primarily driven by increased sales of its product Nefecon in commercialized markets.The company stated that 2026 will be a critical \"year of execution\" for its strategic goals, with Nefecon expected to remain the core growth engine for sales revenue. EVEREST MED plans to advance the inclusion of its products in national reimbursement negotiations, accelerate global clinical development of its pipeline, seek partnership opportunities, and expand its therapeutic coverage, contributing to the positive market sentiment.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1119261107","isCrawlerRequest":true}